Prime Medicine
PRME
83 hedge funds and large institutions have $472M invested in Prime Medicine in 2023 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 35 increasing their positions, 15 reducing their positions, and 6 closing their positions.
870% more call options, than puts
Call options by funds: $97K | Put options by funds: $10K
133% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 15
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
5% more funds holding
Funds holding: 79 → 83 (+4)
3.45% more ownership
Funds ownership: 47.45% → 50.89% (+3.4%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
30% less capital invested
Capital invested by funds: $676M → $472M (-$203M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$14M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.02M |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$7.42M |
| 4 |
NAMA
Nikko Asset Management Americas
New York
|
+$7.41M |
| 5 |
BlackRock
New York
|
+$5.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$5.82M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$5.77M |
| 3 |
Millennium Management
New York
|
-$3.76M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.08M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.52M |
PRME Hedge Fund Activity: Q3 2023 in Review
83 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Prime Medicine (PRME) for Q3 2023, worth a combined $472M — down 30% from $676M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new PRME positions and 6 closed out — a net gain of 5 holders — while 35 added to existing stakes and 15 trimmed.
The largest buyer was State Street, adding an estimated $14M. The largest seller was Jane Street, exiting entirely with an estimated $5.82M sold.
- 83 institutional investors held Prime Medicine (PRME) as of Q3 2023, up from 79 in Q2 2023.
- Funds reported $472M of Prime Medicine stock for Q3 2023, down 30% quarter-over-quarter.
- 11 funds opened new Prime Medicine positions in Q3 2023 and 6 closed out, a net change of +5 holders.
- The largest Prime Medicine buyer in Q3 2023 was State Street, an estimated $14M added.
- The largest Prime Medicine seller in Q3 2023 was Jane Street, an estimated $5.82M sold.
Based on aggregated 13F filings for Q3 2023.